This article, “Unveiling the Potential of Antibody-Drug Conjugates,” is an excellent industry review that provides a panoramic view of the hot field of Antibody-Drug Conjugates (ADCs). Next, we will journey from history to the future, delving into molecular mechanisms and clinical practices, connecting textbook knowledge to cutting-edge research. A Precision Guided “Trojan Horse”: An In-Depth … Read more
Broad Moneywort: Also known as: Ground Moneywort, Copper Coin Grass, Horsetail Fragrance, False Peanut. [Source] It is the whole herb of the plant Desmodium styracifolium (Osbeck) Merr. from the legume family. [Morphological Characteristics] Semi-shrubby herb, up to 1 m tall. The stems are prostrate or oblique, with a woody base, and the branches are cylindrical, … Read more
After nearly 30 years of development, the ADC platform has been established, with 12 approved products by the FDA and many more in development. This article aims to provide guidance for clinical researchers on the effective design of clinical protocols and the lessons learned from ADCs. 01Introduction In cancer treatment, compared to novel immunotherapy targets … Read more
Recently, the ADC (Antibody-Drug Conjugate) conference has been held one after another, with major biotech companies competing to report their ADC pipelines. It is expected that 2024 will still be the main stage for ADCs. Developing an entry-level ADC seems not too difficult, but how to evaluate the pharmacology and toxicology in the preclinical stage … Read more
Click the above Xingzhou Drug ▲ Follow This year, CED released the draft for comments on the “Technical Guidelines for Non-Clinical Research of Antibody-Drug Conjugates (ADC)”, which provides assistance for companies conducting non-clinical research on ADCs.It provides guidance on non-clinical studies such as “pharmacology, safety pharmacology, pharmacokinetics, and toxicology”. (1) PharmacologyIn the early development of … Read more
Introduction Antibody-drug conjugates (ADC) are formed by linking monoclonal antibodies that target specific antigens to small-molecule cytotoxic drugs through linkers, combining the powerful killing effects of traditional small-molecule chemotherapy with the tumor-targeting properties of antibody drugs. Since the first ADC (Gemtuzumab-ozogamicin (brand name: Mylotarg)) was approved for the treatment of CD33-positive acute myeloid leukemia, dozens … Read more
Author｜Wenxin As of now, regarding thetoxicity of ADCs in solid tumors and preventive measures, the following is known: ① The indications for ADCs are rapidly expanding, gradually shifting from late-stage to early-stage, and from single therapy to combination strategies. ② The toxicity characteristics of most ADCs are similar to the cytotoxicity of their payloads. ③ … Read more
This year, CED released the draft for “Technical Guidelines for Non-Clinical Research of Antibody-Drug Conjugates” to assist companies in conducting non-clinical research on ADCs.It provides guidance on non-clinical studies such as “pharmacology, safety pharmacology, pharmacokinetics, and toxicology.”(1) PharmacologyIn the early development of ADCs, studies on the in vitro and in vivo pharmacological/efficacy effects of ADCs … Read more
Click to follow Xiaobai Learning Medicine BispecificADC is an active frontier, and today we will discuss whether bispecificADC is more effective than traditional monoclonal ADC in tumor toxin enrichment. Bispecific antibodies can be divided into two main categories: one type binds to two different antigens on different cells, acting as a connector, such as several … Read more
Introduction As one of the most active innovative drug development areas at present, Antibody-Drug Conjugates (ADCs) are rising at an astonishing pace. The global industry interest continues to heat up, with ADC innovative drugs being approved one after another. As of March 2025, a total of 17 ADC products have been approved for market release … Read more